Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Clinical and Diagnostic Laboratory Immunology|February 9, 2005
Approach to validating an opsonophagocytic assay for Streptococcus pneumoniaeBranda T Hu, Xinhong Yu, Thomas R Jones, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|August 30, 2008
Time series analysis of treatment adherence patterns in individuals with obstructive sleep apneaMark S Aloia, Matthew S Goodwin, Wayne F Velicer, et al.
The International Journal of Biochemistry & Cell Biology|February 21, 2002
Characterization of platelet-derived growth factor-C (PDGF-C): expression in normal and tumor cells, biological activity and chromosomal localizationJoyce Dijkmans, Jean Xu, Stefan Masure, et al.
European Journal of Neurology|July 22, 2021
Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Nucleosome-mediated conformational switches in micro-eccDNAsSarah Harris, Victor Velasco Berrelleza, William Sandel, et al.
The Journal of Allergy and Clinical Immunology|May 15, 2020
An anti-IL-13 antibody reverses epithelial-mesenchymal transition biomarkers in eosinophilic esophagitis: Phase 2 trial resultsPeter H Gann, Ryan J Deaton, Nathan McMahon, et al.
The Neurodiagnostic Journal|June 2, 2026
An Analysis of the Response Time to the Push Button in the Epilepsy Monitoring UnitSukriye Damla Kara, Sydney Bhopatkar, Daniel T Trussell, et al.
Digestive Diseases and Sciences|April 3, 2024
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's DiseaseSarah Harris, Brian G Feagan, Stephen Hanauer, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 23, 2020
Safe nanoengineering and incorporation of transplant populations in a neurosurgical grade biomaterial, DuraGen PlusTM, for protected cell therapy applicationsLouise Finch, Sarah Harris, Georgios Solomou, et al.
European Journal of Neurology|June 4, 2025
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod TrialsSarah Harris, Giancarlo Comi, Bruce A C Cree, et al.
Pageof 18